Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-12 | Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University. His expertise is in drug development with particular expertise in hematologic malignancies. |
| 2022-03-29 | Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University. He has extensive clinical development experience but no software-related skills. |
| 2023-03-23 | Stanley R. Frankel, M.D., has served on our Board of Directors since April 2021. Dr. Frankel is a hematologist-oncologist with extensive academic and industry experience in the research, clinical development, and commercialization of immuno-oncology and cellular therapies... Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University. |
| 2023-12-04 | Stanley R. Frankel, M.D.(8) Consists of (a) 1,500 shares of common stock and (b) 214,998 shares of common stock underlying options exercisable within 60 days of November 15, 2023. |
| 2024-04-25 | Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University, and has been a board-certified licensed physician since 1986. |
Data sourced from SEC filings. Last updated: 2026-03-09